Cargando…

Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long‐term follow‐up of the ESCAPE study

BACKGROUND: Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin. The goal of the current study was to evaluate the effect of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Minji, Chun, Eun Ju, Lim, Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426278/ https://www.ncbi.nlm.nih.gov/pubmed/35932165 http://dx.doi.org/10.1111/1753-0407.13300

Ejemplares similares

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
por: Sohn, Minji, et al.
Publicado: (2023)

Efficacy of Cilostazol on Uncontrolled Coronary Vasospastic Angina: A Pilot Study
por: Yoo, Sang-Yong, et al.
Publicado: (2013)

Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits
por: Wang, Yanli, et al.
Publicado: (2015)

Four‐year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
por: Miao, Benjamin, et al.
Publicado: (2020)

Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long‐Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)
por: Yamasaki, Yoshimitsu, et al.
Publicado: (2006)

Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events
por: Versteylen, Mathijs O., et al.
Publicado: (2011)

Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome
por: Zhang, Lei, et al.
Publicado: (2022)

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
por: Jeon, Minji, et al.
Publicado: (2021)

Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?
por: Montalto, Massimo, et al.
Publicado: (2011)

Efficacy of cilostazol in canine bradyarrhythmia
por: Ohmori, Takahiro, et al.
Publicado: (2022)

A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Kong, Shuting, et al.
Publicado: (2021)

Long term effects of cilostazol in a dog with sick sinus syndrome
por: KANNO, Nobuyuki, et al.
Publicado: (2017)

Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease
por: Wu, Chung-Kuan, et al.
Publicado: (2023)

Clinical characteristics of patients with premature acute coronary syndrome and adverse cardiovascular events after PCI
por: Shi, Xiao-Jun, et al.
Publicado: (2019)

Galectin-1 is associated with the severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography
por: Chou, Ruey-Hsing, et al.
Publicado: (2020)

Heart Rate Fragmentation as a Novel Biomarker of Adverse Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis
por: Costa, Madalena D., et al.
Publicado: (2018)

Pattern of adverse events of antiepileptic drugs: results of the aESCAPE study in Poland
por: Chmielewska, Barbara, et al.
Publicado: (2013)

Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks
por: Sohn, Minji, et al.
Publicado: (2021)

A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
por: Lin, Jia-Ling, et al.
Publicado: (2022)

Total and differential WBC counts are related with coronary artery atherosclerosis and increase the risk for cardiovascular disease in Koreans
por: Kim, Jung Hee, et al.
Publicado: (2017)

Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications
por: Rychter, Marek, et al.
Publicado: (2018)

Editorial: Advances in predicting future adverse coronary events: the role of cardiovascular imaging and coronary physiology indices
por: Seitun, Sara, et al.
Publicado: (2023)

Author Correction: Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks
por: Sohn, Minji, et al.
Publicado: (2021)

Pharmacological Potential of Cilostazol for Alzheimer’s Disease
por: Ono, Kenjiro, et al.
Publicado: (2019)

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database
por: Noh, Yoojin, et al.
Publicado: (2016)

Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis
por: Karpouzas, George Athanasios, et al.
Publicado: (2022)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials
por: Bangalore, Sripal, et al.
Publicado: (2014)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel.
por: Ahn, Jeong Cheon, et al.
Publicado: (2004)

The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease
por: Mori, Hiroyoshi, et al.
Publicado: (2016)

Carotid Atherosclerosis Progression and Risk of Cardiovascular Events in a Community in Taiwan
por: Chen, Pei-Chun, et al.
Publicado: (2016)

Long-term cardiovascular adverse events in very elderly COVID-19 patients
por: Karadavut, Serhat, et al.
Publicado: (2022)

Cilostazol attenuates kainic acid-induced hippocampal cell death
por: Park, Young-Seop, et al.
Publicado: (2018)

Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs
por: Zhao, Zhiqiang, et al.
Publicado: (2016)

Long-term management of high-grade atrioventricular block using cilostazol in a cat
por: Iwasa, Naoki, et al.
Publicado: (2019)

Artificial Intelligence Advancements in the Cardiovascular Imaging of Coronary Atherosclerosis
por: Covas, Pedro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2mks7megd6dd6mu55gks2dmo2g